Drug price control in India - an ongoing debate (Record no. 521793)

000 -LEADER
fixed length control field 00918nam a22001457a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 230227b ||||| |||| 00| 0 eng d
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Narayanan, Krithiga
245 ## - TITLE STATEMENT
Title Drug price control in India - an ongoing debate
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Place of publication, distribution, etc Economic and Political Weekly
300 ## - PHYSICAL DESCRIPTION
Extent 57(50), Dec, 10, 2022: p.17-20
520 ## - SUMMARY, ETC.
Summary, etc Price control of life-saving essential medicines is the need of the hour, but the National Pharmaceutical Pricing Authority has allowed a hike of 10% in nearly 800 drugs and devices listed under the National List of Essential Medicines from 1 April 2022 because of the rising input costs. Prices of scheduled drugs are allowed an increase each year acc¬ording to the wholesale price index. Input costs are rising primarily because India is heavily dependent on China for drug imports.- Reproduced
773 ## - HOST ITEM ENTRY
Main entry heading Economic and Political Weekly
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
Subject DIP DRUGS
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Item type Articles
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Permanent location Current location Date acquired Serial Enumeration / chronology Barcode Date last seen Koha item type
          Indian Institute of Public Administration Indian Institute of Public Administration 2023-02-27 50(57), Dec, 10, 2022: p.17-20 AR128115 2023-02-27 Articles

Powered by Koha